New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:30 EDTCELGNICE says better information needed on Celgene's Revlimid
The National Institute for Health and Care Excellence, the U.K.'s healthcare guidance body, issued new draft guidance on the use of Revlimid's lenalidomide, trade name Celgene, for treating the blood cancer multiple myeloma after one prior treatment with bortezomib. NICE said, "With the current information available, the committee's preliminary guidance, now being issued for consultation, does not recommend lenalidomide for this indication." NICE's Chief Executive, Sir Andrew Dillon, said: “In the original guidance published in 2009, NICE recommended lenalidomide as treatment option for multiple myeloma in people who have received two or more prior therapies. This recommendation has not changed and patients at that stage in the treatment pathway will still be able to receive lenalidomide through the NHS." Reference Link
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
13:44 EDTCELGCelgene price target raised to $155 from $130 at Argus
Argus increased its price target on Celgene as the firm thinks the company is "well on its way" to meeting its growth targets. The firm thinks the company reported strong Q4 results and keeps a Buy rating on the shares.
February 24, 2015
08:04 EDTCELGCelgene reports Abraxane now reimbursed in Italy as first-line treatment
Celgene International Sārl, a wholly owned subsidiary of Celgene Corporation, announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANE -- paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel -- in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. The reimbursement decision has been published in the Italian Official Gazette no. 30, dated February 6, 2015.
07:31 EDTCELGRBC Capital to hold a conference
Subscribe for More Information
February 20, 2015
16:03 EDTCELGOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information
February 18, 2015
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
February 13, 2015
08:19 EDTCELGAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information
05:38 EDTCELGCelgene volatility increases on wide price movement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use